Axogen, INC 10-Q quarterly reports

Axogen Inc. announced its financial results for the second quarter ended June 30, 2026, reporting a 23.1% increase in revenue compared to the prior year period.

Axogen Inc. reported a 26.6% increase in Q1 2026 revenue to $61.5 million, but its net loss widened to $19.6 million.

Axogen, Inc. reported a significant increase in third-quarter revenue and a shift to net income, alongside reduced net losses for the nine-month period, despite an FDA BLA review extension.

Axogen, Inc. reported a net income of $579,000 for the second quarter of 2025, a significant improvement from a net loss in the prior year, driven by an 18.3% increase in revenues.

Axogen, Inc. announces a 17.4% increase in revenue for the first quarter of 2025 and highlights progress in its Biologics License Application (BLA) for Avance Nerve Graft.

Axogen, Inc. announced a 17.9% increase in revenue for the third quarter of 2024 and the FDA's acceptance of their Biologics License Application (BLA) for Avance Nerve Graft.

Axogen, Inc. announced a 25.6% increase in revenue for the second quarter of 2024, alongside advancements in their BLA submission for Avance Nerve Graft.

Axogen, Inc. announced a 12.9% increase in revenue for the first quarter of 2024, alongside progress in its Biologics License Application (BLA) for Avance Nerve Graft and the limited launch of Avive+ Soft Tissue Matrix.